Budesonide Inhaler Market is Develop Rapidly 2019: Pfizer Inc., Cipla Limited, Lupin Limited, Cosmo Pharmaceuticals, Takeda Pharmaceutical Company Ltd., Manus Aktteva Biopharma LLP, Abbott Laboratories, Lunan Better Pharmaceutical, Novartis International

The global demand for budesonide inhaler is expected to witness substantial growth over the forecast period, owing to increasing incidences and prevalence of asthma. According to the Global Asthma Report 2018, asthma causes around 1000 deaths every day and affects as many as 339 million people worldwide.

Free Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/2551

Furthermore, major players in the market are focused on developing new drug combinations for paediatric use. For instance, in January 2017, AstraZeneca announced that the U.S. FDA approved Symbicort (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of asthma in paediatric patients aged 6 to 12 years. Budesonide/formoterol is already approved in the U.S. to treat asthma in patients 12 years and older and for the maintenance treatment of airflow obstruction in Chronic Obstructive Pulmonary Disease (COPD) in adults.

However, product recalls due to failure to meet regulatory guidelines is expected to hinder the market growth. For instance, in 2014, AstraZeneca’s PULMICORT RESPULES (budesonide inhalation suspension) was recalled by the U.S. FDA as budesonide may be above or below the specification range, which can be harmful for the patients.

Key players in the market are focused on developing generics version of budesonide inhaler in affordable prices and in various forms such as dry powder, aerosols, suspensions or spray for asthma patients. Increasing number of regulatory approvals for generic versions of budesonide inhaler is a major factor driving growth of the budesonide inhaler market. For instance, in 2018, Lupin received approval for its budesonide inhalation suspension 0.5/2ml single dose ampules from the U.S.FDA to market generic versions AstraZeneca’s Pulmicort Respules. It is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age.

Moreover, key manufacturers are also focused on developing new combinations of budesonide inhaler with other drugs to enhance their market share. Budesonide can be made in combination with formoterol. In September 2016, Orion Corporation announced that it has entered into a collaboration agreement with Menarini Group for the co-marketing of budesonide-formoterol Easyhaler combination product in Germany, Italy, Spain, and Portugal. Budesonide-formoterol Easyhaler is an inhaled combination product indicated for asthma and chronic obstructive pulmonary disease (COPD). In this formulation, budesonide acts as an anti-inflammatory agent and formoterol acts as a long-acting bronchodilator. The product is available under the brand name Bufomix Easyhaler in most of the European countries.

Get Free PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2551

Key players operating in the global budesonide inhaler market include, Pfizer Inc., Cipla Limited, Lupin Limited, Cosmo Pharmaceuticals, Takeda Pharmaceutical Company Ltd., Manus Aktteva Biopharma LLP, Abbott Laboratories, Lunan Better Pharmaceutical, Novartis International AG (Sandoz), Mylan N.V., Skyepharma, AstraZeneca Plc., Chiesi Farmaceutici S.p.A, Orion Corporation, Santarus Inc., Synmosa Biopharma Corporation, and Shanghai Sine Pharmaceutical Laboratories Co. Ltd.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.